Pharma company Lupin Thursday said the US health regulator has approved its marketing of generic version of Gilead Sciences, Inc's Ranexa tablets, a drug used to treat heart disease in the American market.
The company's US-based subsidiary Lupin Pharmaceuticals Inc has received final approval for its Ranolazine Extended-release tablets, 500 mg and 1000 mg from the US Food and Drugs Administration (USFDA), Lupin Ltd said in a statement.
"Lupin believes that it is the first applicant to file an abbreviated new drug application (ANDA) for Ranexa Extended-release tablets 500mg and 1000mg strengths and as such will be entitled to 180 days of marketing exclusivity," it said.
Ranolazine Extended-release tablets are indicated for treatment of chronic angina.
According to IMS Health, the tablets posted sales of around $443.4 million in the US for 12 months ending March 2013.
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app